The inhibition of HIV-1’s replicative machinery remains a cornerstone in the battle against AIDS. Central to this approach are inhibitors targeting reverse transcriptase (RT) and integrase. Reverse ...

Background. Factors promoting the emergence of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) connection domain mutations and their effect on antiretroviral therapy (ART) are ...

Of three enzymes encoded by HIV–reverse transcriptase, protease, and integrase—only the first two have been exploited clinically as inhibitor targets. Efforts to develop inhibitors of purified ...

A mutation in a little-studied structural region of the AIDS virus can cause resistance to several HIV drugs, according to a study. Several mutations in reverse transcriptase (RT), the viral enzyme ...

Tenofovir was approved by the Food and Drug Administration (FDA) in October 2001 through an accelerated approval process; it is the first nucleotide analogue reverse-transcriptase inhibitor marketed ...

REDWOOD CITY, Calif., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the launch of its ...

The crystal structure of a human endogenous reverse transcriptase has similarities to HIV reverse transcriptase, a well-known tractable drug target, which will help design drugs to treat cancer and ...

Clin Drug Invest. 2007;27(8):509-531. Because of its poor tolerability, regimen complexity and drug-interaction potential relative to other new NRTIs, use of didanosine has decreased over the last few ...

The crystal structure of a human endogenous reverse transcriptase has similarities to HIV reverse transcriptase, a well-known tractable drug target, which will help design drugs to treat cancer and ...

FDA Announces Baraclude (entecavir) is Not Recommended for HIV/HBV Co-infected Patients Who Are Not Also Receiving HAART Due to the Potential for the Development of HIV Resistance ROCKVILLE, Md., Aug.